Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;4(4):492-498.
doi: 10.1002/ehf2.12237.

Muscle wasting and sarcopenia in heart failure and beyond: update 2017

Jochen Springer  1 , Joshua-I Springer  1 , Stefan D Anker  2
Affiliations
Review

Muscle wasting and sarcopenia in heart failure and beyond: update 2017

Jochen Springer et al. ESC Heart Fail. 2017 Nov.

Abstract

Sarcopenia (loss of muscle mass and muscle function) is a strong predictor of frailty, disability and mortality in older persons and may also occur in obese subjects. The prevalence of sarcopenia is increased in patients suffering from chronic heart failure. However, there are currently few therapy options. The main intervention is resistance exercise, either alone or in combination with nutritional support, which seems to enhance the beneficial effects of training. Also, testosterone has been shown to increased muscle power and function; however, a possible limitation is the side effects of testosterone. Other investigational drugs include selective androgen receptor modulators, growth hormone, IGF-1, compounds targeting myostatin signaling, which have their own set of side effects. There are abundant prospective targets for improving muscle function in the elderly with or without chronic heart failure, and the continuing development of new treatment strategies and compounds for sarcopenia and cardiac cachexia makes this field an exciting one.

Keywords: Cardiac cachexia; Muscle wasting; Sarcopenia.

PubMed Disclaimer

References

    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200. - PubMed
    1. Edelmann F. Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction. ESC Heart Fail. 2015; 2: 41–45. - PMC - PubMed
    1. Lam CSP. Heart failure in Southeast Asia: facts and numbers. ESC Heart Fail. 2015; 2: 46–49. - PMC - PubMed
    1. Konishi M, Ishida J, Springer J, Anker SD, von Haehling S. Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact. J Cachexia Sarcopenia Muscle 2016; 7: 515–519. - PMC - PubMed
    1. Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, Anker SD. Heart failure epidemiology and novel treatments in Japan: facts and numbers. ESC Heart Fail. 2016; 3: 145–151. - PMC - PubMed

MeSH terms